The Drug Enforcement Administration (DEA) seems to have taken a turn with its proposal for an increase in the production of psilocybin and marijuana. The purpose of this increased production will be used for research purposes under the pretext of trying to develop new therapeutic medications.
Although federally illegal in the United States for recreational use, the DEA has stated that it supports the research of controlled substances in a well-regulated manner. Examples of schedule 1 substances are psilocybin, marijuana, and psilocin, which are being heavily researched by the DEA. Although the agency has on several occasions produced schedule 1 drugs such as cannabis, this demand for research shows almost something of a 180-degree turn in the agenda of the DEA.
For some perspective on how much the DEA wants to research these potentially therapeutic remedies. The DEA plans to produce 2 million grams of marijuana within 2021 alone. This would entail a drastic increase in the production of cannabis and cannabis extracts. Furthermore, the DEA has also decided to increase the production of psilocybin from a quota of 50 grams to 1500 grams, a 2900% increase.
Federal courts nonetheless still present a roadblock as the Fed has dismissed petitions to change their cannabis’s scheduling under the Controlled Substances Act. However, developments in production still suggest a promising future for the future of therapeutic medicine. Nonetheless, many are still frustrated that these plants and fungi with what could be an actual value to help others are under strict control in the first place.